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Objective. To investigate the impact of an exper-
imental model of osteoarthritis (OA) on spinal nocicep-
tive processing and the role of the inhibitory endocan-
nabinoid system in regulating sensory processing at the
spinal level.
Methods. Experimental OA was induced in rats
by intraarticular injection of sodium mono-iodoacetate
(MIA), and the development of pain behavior was
assessed. Extracellular single-unit recordings of wide
dynamic range (WDR) neurons in the dorsal horn were
obtained in MIA-treated rats and saline-treated rats.
The levels of endocannabinoids and the protein and
messenger RNA levels of the main synthetic enzymes for
the endocannabinoids (N-acyl phosphatidylethanol-
amine phospholipase D [NAPE-PLD] and diacylglyc-
erol lipase  [DAGL]) in the spinal cord were mea-
sured.
Results. Low-weight (10 gm) mechanically evoked
responses of WDR neurons were significantly (P < 0.05)
facilitated 28 days after MIA injection compared with
the responses in saline-treated rats, and spinal cord
levels of anandamide and 2-arachidonoyl glycerol
(2-AG) were increased in MIA-treated rats. Protein
levels of NAPE-PLD and DAGL, which synthesize
anandamide and 2-AG, respectively, were elevated in the
spinal cords of MIA-treated rats. The functional role of
endocannabinoids in the spinal cords of MIA-treated
rats was increased via activation of cannabinoid 1 (CB1)
and CB2 receptors, and blockade of the catabolism of
anandamide had significantly greater inhibitory effects
in MIA-treated rats compared with control rats.
Conclusion. Our findings provide new evidence
for altered spinal nociceptive processing indicative of
central sensitization and for adaptive changes in the
spinal cord endocannabinoid system in an experimental
model of OA. The novel control of spinal cord neuronal
responses by spinal cord CB2 receptors suggests that
this receptor system may be an important target for the
modulation of pain in OA.
Joint disease such as osteoarthritis (OA) is asso-
ciated with chronic pain (1). The mechanisms underlying
OA pain are widely acknowledged to be complex. Re-
cent evidence suggests that central sensitization may
contribute to pain in patients with OA (2). Studies using
models of knee joint pathology are essential for further
understanding of the mechanisms leading to chronic
pain in patients with OA. Intraarticular injection of the
glycolysis inhibitor sodium mono-iodoacetate (MIA)
produces cartilage and subchondral bone pathology con-
sistent with that seen in human OA joints (3,4) and a
pronounced decrease in weight-bearing on the injured
hind limb (5–7), indicative of hyperalgesia. Furthermore,
Supported by Wellcome Trust grant 078773/Z/05/Z. Dr.
Sagar’s work was supported by the Wellcome Trust. Ms Staniaszek and
Mr. Woodhams’ work was supported by GlaxoSmithKline and by
Medical Research Council studentships. Mr. Okine and Dr. Norris’
work was supported by Medical Research Council studentships.
1Devi Rani Sagar, PhD, Lydia E. Staniaszek, PhD, Bright N.
Okine, MSc, Stephen Woodhams, MSc, Leonie M. Norris, PhD,
Richard G. Pearson, PhD, Michael J. Garle, PhD, Stephen P. H.
Alexander, PhD, Andrew J. Bennett, PhD, David A. Kendall, PhD,
Brigitte E. Scammell, MB ChB, DM, FRCS(Ortho), Victoria Chap-
man, PhD: University of Nottingham and Queen’s Medical Centre,
Nottingham, UK; 2David A. Barrett, PhD: University of Nottingham,
Nottingham, UK.
Address correspondence and reprint requests to Devi Rani
Sagar, PhD, School of Biomedical Sciences, Medical School, Queen’s
Medical Centre, Nottingham NG7 2UH, UK. E-mail: devi.sagar@
nottingham.ac.uk.
Submitted for publication April 15, 2010; accepted in revised
form August 3, 2010.
3666
consistent with the notion of central sensitization, tactile
allodynia is exhibited by the hind paw ipsilateral to the
joint pathology (6,8). These behavioral data suggest that
there are changes in spinal cord processing of afferent
input in this model of OA pain. This is consistent with
the observation that sensitization of joint nociceptors
increases the peripheral receptive field size of neurons
innervating the knee joint, paw, and ankle in rats (9).
The endocannabinoids have well-described roles
in the modulation of nociceptive processing (10). In-
deed, increased activity of the nociceptive pathways is
associated with increased levels of the endocannabi-
noids, particularly anandamide, in the dorsal root gan-
glia (11) and spinal cord (12,13) in models of neuro-
pathic pain. Importantly, there is evidence for increased
peripheral endocannabinoid-mediated control of the
mechanosensitivity of afferent nerve fibers in the
MIA-induced OA model (14). Elevated levels of endo-
cannabinoids in models of chronic pain are likely to
counteract the increased neuronal activity driven by
afferent input and, therefore, may provide inhibitory
modulation of the mechanisms driving central sensitiza-
tion. Maintenance of these elevated levels of endocan-
nabinoids by the manipulation of catabolic enzymes is
effective for decreasing pain behavior in other models of
pain (10).
The aim of this study was to investigate the
relationship between joint pathology, tactile allodynia,
and spinal neuron responses in the MIA model of OA
pain and to determine whether spinal cord endocannabi-
noids tonically control the noxious versus innocuous
responses of neurons. We report, for the first time, that
this experimental model of OA is associated with in-
creased spinal cord levels of the inhibitory endocannabi-
noids anandamide and 2-arachidonoyl glycerol (2-AG)
and increased protein levels of the major enzymes
responsible for their synthesis, N-acyl phosphatidyleth-
anolamine phospholipase D (NAPE-PLD) and diacyl-
glycerol lipase  (DAGL). We demonstrate
endocannabinoid-mediated inhibitory control of spinal
cord neuronal responses via the activation of spinal
cannabinoid 1 (CB1) receptors and a novel functional
role of spinal CB2 receptors. Blockade of endocannabi-
noid catabolism by the fatty acid amide hydrolase
(FAAH) inhibitor URB597 inhibited low weight–
evoked neuronal responses in the rat model of OA, but
not in control rats, further supporting the notion of a
novel functional role of spinal cord endocannabinoids in
this model of OA.
MATERIALS AND METHODS
Animals. Studies were carried out in accordance with
the UK Home Office Animals (Scientific Procedures) Act
(1986) and followed the guidelines of the International Asso-
ciation for the Study of Pain. A total of 188 male Sprague-
Dawley rats (obtained from Charles River UK) weighing
160–190 gm were used. Anesthetized rats received a single
intraarticular injection of MIA (0.3 mg/50 l, 1 mg/50 l, or 3
mg/50 l, based on previous studies) in saline through the
infrapatellar ligament of the left knee.
Behavioral testing. The experimenter was blinded to
treatments. Baseline measurements were obtained immedi-
ately prior to intraarticular injection (postoperative day 0) and
then from postoperative day 2 to day 28. The effects of
intraarticular injection of MIA or saline on weight distribution
through the left (ipsilateral) and right (contralateral) knee
were assessed using a Linton Incapacitance Tester (Linton
Instrumentation), as previously described (15). The develop-
ment of hind paw tactile allodynia was assessed using von Frey
monofilaments (Semmes-Weinstein monofilaments [bending
forces of 1 gm, 1.4 gm, 2 gm, 4 gm, 6 gm, 8 gm, 10 gm, and 15
gm]), as previously described (16). Von Frey monofilaments
were applied, in ascending order of bending force, to the
plantar surface of both hind paws. The lowest weight of
monofilament that elicited a withdrawal reflex was recorded as
the paw withdrawal threshold.
In vivo electrophysiology. The methods used were
similar to those previously described by Chapman et al (17).
Rats were anesthetized with isoflurane (3% for induction, 2%
during surgery, 1–1.5% for maintenance in 66% N2O, 33%
O2), placed in a stereotaxic frame, and a laminectomy was
performed to expose segments L4–L5 of the spinal cord. Core
body temperature was maintained at 36.5–37.5°C. Extracellu-
lar single-unit recordings of deep wide dynamic range (WDR)
dorsal horn neurons were obtained with glass-coated tungsten
microelectrodes. Action potentials were digitized and analyzed
using a CED micro1401 interface and Spike 2 software (Cam-
bridge Electronic Design). Neurons that responded to brush
and pinch stimuli were identified, and their depths from the
spinal cord surface were recorded (mean  SEM depth of
neurons 806  16 m). The responses of WDR neurons to
mechanical punctate stimuli applied to the peripheral recep-
tive field on the hind paw were characterized. Von Frey
monofilaments (Semmes-Weinstein monofilaments, calibra-
tion codes 5.07, 5.18, 5.46 corresponding to bending forces of
10 gm, 15 gm, and 26 gm, respectively) were applied to the
plantar surface of the receptive field for 10 seconds, as
previously described (16); the number of evoked action poten-
tials was recorded, and the frequency of firing over this period
of time was calculated. Data are expressed as the mean
frequency of firing or as the percent of pre–drug control
responses.
Spinal drug administration. One WDR neuron per rat
was used for the pharmacologic studies. The effects of direct
spinal administration of the CB1 receptor antagonist AM251
(0.1–10 g/50 l; n  6 neurons in 6 MIA-treated rats and
n  6 neurons in 6 saline-treated rats) or vehicle (3% Tween
80 in saline; n  6 neurons in 6 MIA-treated rats and n  6
neurons in 6 saline-treated rats) on mechanically evoked
responses (as described above) of WDR neurons were studied.
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In a separate group of rats, the effects of spinal administration
of the CB2 receptor antagonist SR144528 (0.001–0.1 g/50 l)
on mechanically evoked responses of WDR neurons were
studied (n  6 neurons in 6 MIA-treated rats and n  6
neurons in 6 saline-treated rats). Note that the same vehicle
was used for AM251 and SR144528. The effects of inhibiting
catabolism of the endocannabinoids by FAAH with URB597
(10–50 g/50 l) (18) on mechanically evoked responses of
WDR neurons were studied (n  6 neurons in 6 MIA-treated
rats and n  6 neurons in 6 saline-treated rats). The same
vehicle as that described above was also used for URB597.
Measurement of endocannabinoids. In separate
groups of MIA- and saline-treated rats, spinal cord levels of
endocannabinoids on days 14 and 28 postinjection (n 10 rats
per group) were measured using an established method (19),
with minor modifications as indicated below. The ipsilateral
and contralateral lumbar spinal cord was dissected and stored
at 80°C; samples were minced and added to ice-cold aceto-
nitrile containing internal standards (0.42 nmoles d8-
anandamide, 1.5 nmoles d8–2-AG). Simultaneous measure-
ment of endocannabinoids and related compounds was then
performed using liquid chromatography–tandem mass spec-
trometry. Analysis was carried out on an Agilent 1100 system
coupled to a Quattro Ultima triple quadrupole mass spectrom-
eter (Waters) in electrospray-positive mode. Analytes were
separated chromatographically on a Waters Symmetry C18
column (internal diameter 100 2.1 mm, particle size 3.5 m),
with a mobile phase flow rate of 0.3 ml/minute. Multiple-
reaction monitoring of individual compounds, using specific
precursor and product mass/charge ratios, allowed simulta-
neous measurement of anandamide, 2-AG, palmitoylethanol-
amide (PEA), and oleolylethanolamide (OEA).
Enzyme assays. In an additional cohort of MIA-
treated rats and saline-treated rats, the ipsilateral and con-
tralateral lumbar spinal cord was dissected on days 14 and 28
postinjection and stored at 80°C (n  6 rats per group).
FAAH and monoacylglycerol lipase (MAGL) activities were
assessed in postnuclear supernatant samples (1,000 gm) in the
presence of 2 M 3H-labeled anandamide and 100 M 3H-
labeled 2-oleoylglycerol (both from American Radiolabeled
Chemicals), respectively, at pH 7.4 (20). Specific FAAH and
MAGL activities were defined by the presence of 10 M
URB597 and 1 M methylarachidonoylfluorophosphonate
(Cayman Europe), respectively.
Antibodies. Mouse primary monoclonal antibodies to
-actin (1:5,000) were obtained from Sigma. Rabbit primary
polyclonal antibodies to FAAH (1:200), MAGL (1:200), and
NAPE-PLD (1:200) were obtained from Cayman, and those to
DAGL (1:200) were obtained from Frontier Bioscience. The
secondary antibodies used were IRDye 680–conjugated goat
polyclonal anti-mouse IgG (1:10,000) and IRDye 800–
conjugated goat polyclonal anti-rabbit IgG (1:10,000) (Li-Cor).
Western blotting. The ipsilateral lumbar spinal cord
was homogenized in 1 ml of radioimmunoprecipitation assay
lysis buffer. The supernatant was separated from the pellet and
assayed for total protein concentration, using the Pierce BCA
Protein Assay Kit. Fifty micrograms of protein was separated
on a 12% sodium dodecyl sulfate–polyacrylamide gel and
transferred onto a Hybond ECL membrane (GE Healthcare
Biosciences) The membrane was incubated overnight at 4°C
with the appropriate primary antibody. Blots were scanned for
densitometric analysis using the Li-Cor Odyssey Infrared Im-
aging System.
RNA extraction and complementary DNA (cDNA)
synthesis. The frozen ipsilateral spinal cord was homogenized
in 2 ml of ice-cold TRI Reagent (Sigma-Aldrich), and RNA
was purified according to the manufacturer’s instructions. For
cDNA synthesis, 250 ng of total RNA was reverse transcribed
using SuperScript III reverse transcriptase (Invitrogen) in a
total reaction volume of 20 l. Reactions were incubated for 10
minutes at 25°C and 1 hour at 50°C, and the reaction was
terminated by incubation at 70°C for 15 minutes.
TaqMan quantitative real-time polymerase chain re-
action (PCR). Gene expression was quantified using the rela-
tive standard curve method based on TaqMan quantitative
real-time PCR, as previously described (21). Primers and
probes (FAM, TAMRA modified) were designed using Primer
Express version 3 software (Applied Biosystems) or were
obtained from previously published work and were synthesized
at MWG Biotech. The primers and probes for MAGL were as
follows: forward primer TGCCATCTCCATCCTAGCAG, re-
verse primer CAAGGATATGTTTGGCAGGAM, probe
ATCCGGAATCTGCATCGACTTTGA. The FAAH probe
and primers were those described by Bortolato et al (22), as
follows: forward primer CTCAAGGAATGCTTCAGC, re-
verse primer GCCCTCATTCAGGCTCAAG, probe
ACAAGGGCCACGACTCCACACTGG. The primers and
probe for NAPE-PLD were as follows: forward primer
CAAGCTCCTCTTTGGAACC, reverse primer CTGGAG-
GAGGACGTAACCAA, probe TATCCCAAACGTGCTCA-
GATGGCT. For DAGL, the primers and probe were as
follows: forward primer ACCTGCGGCATCGGTTAG, re-
verse primer CTTTGTCCGGTGCAACAG, probe CAGCT-
GGTCCCGCCGTCTAAAAGTG.
Joint histology. Joints were fixed in 10% formal saline
and decalcified in an aqueous EDTA solution (14% in distilled
water, pH 7.0, 20°C). Samples were paraffin-embedded, and
5–8-m sections of the central portion of the knee joint, in the
coronal plane, were stained with Safranin O–fast green to show
matrix proteoglycan and overall joint morphology. The medial
and lateral knee compartment tibial plateau cartilage, tibial
subchondral bone, and joint synovium were scored.
Articular cartilage was scored using a modified Osteo-
arthritis Research Society International cartilage histopathol-
ogy assessment system based on a scale of 0–6, where
0  normal, 1  surface intact, 2  surface discontinuity,
3  vertical fissures, 4  erosion, 5  denudation, and 6 
deformation, combined with a stage score (scale of 0–4)
indicating the surface extent of joint involvement (0  no
activity, 1  10%, 2  10–25%, 3  25–50%, and 4 
50%) (23). Subchondral bone was assessed (4) as fol-
lows: 0  no subchondral lesions with cellular infiltration;
1  1–2 subchondral lesions, 5% of the tibial plateau; 2 
2–3 subchondral lesions, 15% of the tibial plateau; 3  4–5
subchondral lesions, 25% of the tibial plateau; and 4 
5 subchondral lesions, 25% of the tibial plateau. Synovial
hyperplasia was assessed as the presence of hypercellularity
(24). A mean score for the medial and lateral joint compart-
ments was obtained (0  lining cell layer 1–2 cells thick, 1 
lining layer 3–5 cells thick, 2  lining layer 6–8 cells thick
and/or mild increase in cellularity, 3 lining cell layer9 cells
thick and/or severe increase in cellularity).
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Statistical analysis. Changes in weight distribution and
the development of mechanical allodynia in MIA-treated
versus saline-treated rats were analyzed using two-way analysis
of variance with Bonferroni’s post hoc test. Comparisons of
mechanically evoked responses of WDR neurons in MIA-
treated and saline-treated rats, endocannabinoid levels in the
spinal cords of MIA-treated and saline-treated rats, and the
effects of drug interventions versus treatment with vehicle on
neuronal responses were performed using a nonparametric
Mann-Whitney test. Changes in messenger RNA (mRNA) and
protein levels in the spinal cords of MIA-treated and saline-
treated rats were analyzed using an unpaired t-test. Correla-
tions between joint histology and between MIA-induced
changes in pain behavior and neuronal responses were per-
formed using a Spearman’s 1-tailed rank correlation test.
RESULTS
Pain behavior in the MIA model of OA. Intraar-
ticular injection of 0.3 mg of MIA did not alter weight-
bearing, compared with saline treatment, on either day
14 (data not shown) or day 28 (mean  SEM 82  4%
of weight on contralateral hind limb), despite changes in
joint pathology in MIA-treated rats on day 28 (Table 1;
additional information available from corresponding
author). MIA at doses of 1 mg and 3 mg produced
changes in joint pathology (Table 1; additional informa-
tion available from corresponding author) and signifi-
cantly decreased weight-bearing on the ipsilateral hind
limb (P  0.01 for 1 mg–treated rats on days 14 and 28,
80  4% and 77  6% of weight on contralateral hind
limb, respectively; P  0.001 for 3 mg–treated rats on
days 14 and 28, 67  6% and 66  8% of weight on
contralateral hind limb, respectively), compared with
saline-treated rats (mean SEM 89 9% and 99 3%
of weight on contralateral hind limb, respectively). Fol-
lowing intraarticular injection of MIA, hind paw with-
drawal thresholds to mechanical punctuate stimulation
were significantly decreased compared with those in rats
receiving saline treatment, over the course of the study
(Figure 1A). Intraarticular injection of MIA did not
alter contralateral hind paw withdrawal thresholds (data
not shown). Intraarticular injection of saline did not
alter weight distribution (data not shown) and hind paw
withdrawal thresholds (Figure 1A), nor did it produce
any pathologic conditions in the joints (Table 1).
Increased excitability of spinal neurons in MIA-
treated rats. On the basis of the behavioral data, the
effects of 1 mg (7 neurons) and 3 mg (11 neurons) of
MIA on neuronal responses were studied on days 14–17.
MIA-treated rats exhibited changes in weight-bearing
and hind paw withdrawal thresholds prior to the elec-
trophysiologic studies. At this time point, the responses
of WDR neurons to mechanical punctuate stimulation
of the hind paw were comparable in MIA-treated and
Table 1. Severity of changes in the cartilage, subchondral bone, and synovium produced by intraarticular injection of mono-iodoacetate (MIA)*
Cartilage Subchondral bone Synovium
Day 14
Saline-treated rats (n  3), median (range) score 0 (0) 0 (0–0.25) 0 (0–0.25)
MIA-treated rats
1 mg (n  6), median (range) score 7.75 (0–24.0) 1.42 (0–3.0) 0.75 (0–2.0)
3 mg (n  4), median (range) score 11.0 (0–24.0) 1.50 (0–3.5) 0.25 (0–2.0)
Weight-bearing, Spearman’s r 0.7188† 0.7312† 0.6212‡
Paw withdrawal thresholds, Spearman’s r 0.3545 0.3068 0.3754
Day 28
Saline-treated rats (n  4), median (range) score 0 (0) 0 (0) 0 (0)
MIA-treated rats
0.3 mg (n  8), median (range) score 6.5 (0.75–19) 0.83 (0.25–2.75) 0.5 (0–1.0)
1 mg (n  8), median (range) score 6.13 (0–24.0) 1.0 (0–3.5) 0 (0–2.0)
3 mg (n  3), median (range) score 24.0 (6.0–24.0) 3.75 (1.0–3.75) 2.75 (0–3.0)
Weight-bearing, Spearman’s r 0.7491§ 0.7453§ 0.5372†
Paw withdrawal thresholds, Spearman’s r 0.5499† 0.5883† 0.3761‡
*Intraarticular injection of 1 mg MIA produced marked and comparable changes in cartilage and subchondral bone on days 14 and 28. The severity
of the changes in cartilage, subchondral bone, and synovium produced by intraarticular injection of 3 mg MIA increased from day 14 to day 28.
Synovitis was mild following the 1-mg dose on day 28 but was evident following the 3-mg dose on day 28. Note that because 0.3 mg MIA produced
no change in pain behavior on day 14, joints were not collected at this time point, and data are not available. MIA-induced changes in weight-bearing
were correlated with changes in cartilage, subchondral bone, and synovium histology on both day 14 (n  13 rats) and day 28 (n  23 rats)
postinjection. Decreases in hind paw withdrawal thresholds were significantly correlated with changes in cartilage subchondral bone and synovium
histology on day 28 but not day 14 following injection of MIA.
† P  0.01.
‡ P  0.05.
§ P  0.001.
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saline-treated rats (11 neurons; data not shown). At the
later time point (days 28–31), when mechanical allo-
dynia was maximal, the effects of MIA (0.3 mg [8
neurons], 1 mg [9 neurons], and 3 mg [11 neurons]) on
the hind paw–evoked responses of WDR neurons were
compared with responses in saline-treated rats (9 neu-
rons). The responses of WDR neurons to innocuous and
noxious mechanical stimulation (10 gm and 15 gm,
respectively) of the hind paw were significantly increased
in MIA (1 mg and 3 mg)–treated rats compared with the
neuronal responses in saline-treated rats (Figure 1B).
Higher-weight (26 gm–evoked) responses of WDR neu-
rons were comparable in MIA-treated rats and saline-
treated rats.
The relationship between joint histology, hyper-
algesia (weight-bearing), and allodynia and the re-
sponses of WDR neurons was investigated. Changes in
cartilage, subchondral bone, and synovium histology
were significantly correlated, on both day 14 and day 28
after MIA injection (data not shown). MIA-induced
changes in cartilage, subchondral bone, and synovium
were significantly correlated with changes in weight-
bearing on day 14 and day 28 after MIA injection
(Table 1). Interestingly, MIA-induced changes in carti-
lage, subchondral bone, and synovium were significantly
correlated with mechanical allodynia on day 28, but not
on day 14, after MIA injection (Table 1). Changes in
weight-bearing and hind paw–evoked responses of
WDR neurons were significantly correlated on day 28,
but not day 14, after MIA injection (Figure 2). These
data emphasize the importance of the later time point
for studying the mechanisms underlying joint pain in this
model.
Increased spinal cord levels of endocannabinoids
in MIA-treated rats. We investigated whether spinal
cord levels of the endocannabinoids are altered in rats
treated with 1 mg of MIA. Levels of 2-AG were signif-
icantly elevated in the ipsilateral spinal cords of MIA-
treated rats compared with saline-treated rats on day 14.
Similarly, levels of 2-AG were significantly increased in
the ipsilateral spinal cords of MIA-treated rats com-
pared with saline-treated rats on day 28 (Figure 3). A
tendency toward bilateral increases in anandamide levels
in the spinal cords of MIA-treated rats compared with
saline-treated rats was observed at both time points, but
significance was reached only for the contralateral spinal
cords (Figure 3). Spinal cord levels of the related
N-acylethanolamines, PEA and OEA, were significantly
elevated in the ipsilateral and contralateral spinal cords
of MIA-treated rats compared with saline-treated rats,
at both time points (Figure 3).
Changes in the levels of endocannabinoids and
the related N-acylethanolamines are unlikely to be at-
tributable to altered catabolism, because neither FAAH
nor MAGL activity was altered in the spinal cords of
MIA-treated rats on day 14 (data not shown) or day 28
(for FAAH activity, mean  SEM 48  7 pmoles/
minute/mg protein for the ipsilateral spinal cord and
41  3 pmoles/minute/mg protein for the contralateral
Figure 1. A, Changes in hind paw withdrawal threshold to mechanical
punctuate stimulation in rats treated with mono-iodoacetate (MIA;
0.3–3 mg) and rats treated with saline.   P  0.05,   P  0.01,
  P  0.001, MIA 3 mg versus saline;   P  0.05,   P 
0.01,   P  0.001, MIA 1 mg versus saline; #  P  0.05, MIA
0.3 mg versus saline, by one-way analysis of variance with Bonferroni’s
post hoc test. B, Responses of wide dynamic range neurons to
mechanical (10–26 gm) punctate stimulation of the peripheral recep-
tive field on the hind paws of MIA-treated (0.3–3 mg/50 l) and
saline-treated rats on days 28–31. Values are the mean  SEM.  
P  0.05;   P  0.01 versus saline, by Mann-Whitney test.
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spinal cord; for MAGL activity, mean  SEM 24  3
pmoles/minute/mg protein for the ipsilateral spinal cord
and 26  3 pmoles/minute/mg protein for the contralat-
eral spinal cord), compared with saline-treated rats (for
FAAH activity, mean  SEM 50  4 pmoles/minute/mg
protein for the ipsilateral spinal cord and 47  2
Figure 2. Changes in weight-bearing and hind paw–evoked responses of wide dynamic range
(WDR) neurons on days 14 and 28 following mono-iodoacetate (MIA) injection. No correlation
between changes in weight-bearing on the MIA-treated joint and innocuous (10 gm) mechanically
evoked responses of WDR neurons was observed 14 days following intraarticular injection of
MIA (r  0.0781). At the 28-day time point, there was a significant (P  0.05) correlation
between 10 gm–evoked responses of WDR neurons of MIA-treated rats and changes in
weight-bearing in these rats (r  0.4139).
Figure 3. Levels of endocannabinoids (2-arachidonyl glycerol [2-AG] and anandamide [AEA]) and related
N-acylethanolamines (oleoylethanolamide [OEA] and palmitoylethanolamide [PEA]) in the spinal cords of rats
treated with mono-iodoacetate (MIA; 1 mg) or saline, 14 and 28 days following intraarticular injection of MIA.
Bars show the median.  and   P  0.05;   P  0.01;   P  0.001, by Mann-Whitney test. Ips 
ipsilateral; Con  contralateral; PO  postoperative day.
ENDOCANNABINOID RECEPTOR SYSTEM IN A RAT MODEL OF OA PAIN 3671
pmoles/minute/mg protein for the contralateral spinal
cord; for MAGL activity, mean  SEM 31  4 pmoles/
minute/mg protein for the ipsilateral spinal cord and
31  7 pmoles/minute/mg protein for the contralateral
spinal cord). Furthermore, levels of FAAH and MAGL
protein and mRNA in the ipsilateral spinal cords of
MIA-treated rats were comparable with levels in saline-
treated rats (Figure 4). In contrast, protein levels of
NAPE-PLD, the major synthetic enzyme for anandam-
ide, PEA, and OEA, were significantly (mean  SEM
78  13%) increased in the ipsilateral spinal cords of
MIA-treated rats on day 28 compared with saline-
treated rats (Figure 4). Levels of NAPE-PLD mRNA
were not altered in MIA-treated rats (Figure 4). Con-
sistent with the elevated levels of 2-AG in MIA-treated
rats, protein levels of the synthetic enzyme DAGL on
day 28 were higher in the ipsilateral spinal cords of
MIA-treated rats compared with saline-treated rats, in
which levels of DAGL were at or below the limits of
detection. DAGL mRNA levels were not altered in
MIA-treated rats.
Spinal endocannabinoids provide greater tonic
modulation of neuronal activity in the MIA model of OA
pain. Because levels of endocannabinoids were elevated
in the spinal cords of MIA-treated rats, the potential
role of endocannabinoids in tonic modulation of the
activity of WDR neurons in MIA-treated rats was
investigated. The mechanically evoked responses of
WDR neurons prior to administration of vehicle or drug
were consistent with those shown in Figure 1B; there
were no significant differences between control values
for the different treatment groups. Spinal administration
of the CB1 receptor antagonist AM251 (0.1–10 g/50 l)
significantly facilitated innocuous (10 gm) and noxious
(26 gm) mechanically evoked responses of WDR neu-
rons in MIA-treated rats (Figure 5). Although the
highest dose of AM251 (10 g/50 l) significantly facil-
itated 10 gm–evoked responses of dorsal horn neurons
in saline-treated rats, the magnitude of the effect of
AM251 was 1.8-fold greater in the MIA-treated rats
compared with saline-treated rats (Figure 5).
Because CB2 receptor expression is up-regulated
in the spinal cord in chronic pain states, we also inves-
tigated whether these receptors provided tonic control
of neuronal responses in the MIA-treated rats. Spinal
administration of the CB2 receptor antagonist SR144528
significantly facilitated both innocuous (10 gm) and
noxious (15–26 gm) mechanically evoked responses of
WDR neurons in MIA-treated rats but did not signifi-
cantly alter evoked responses of WDR neurons in
saline-treated rats (Figure 5).
Figure 4. Comparative analysis of gene and protein expression of
endocannabinoid-metabolizing enzymes in the ipsilateral spinal cord
28 days following intraarticular injection of mono-iodoacetate (MIA)
or saline (Sal). A, Messenger RNA expression of N-acyl phosphati-
dylethanolamine phospholipase D (NAPE-PLD), diacylglycerol lipase
 (DAGL), fatty acid amide hydrolase (FAAH), and monoacylglyc-
eride lipase (MAGL) relative to 18S RNA in saline-treated and
MIA-treated rats. Bars show the mean. B, Top, Densitometric analysis
of protein expression for FAAH, MAGL, NAPE-PLD, and DAGL
relative to -actin in saline-treated and MIA-treated rats. Bars show
the mean and SEM. Bottom, Immunoblots demonstrating elevated
levels of NAPE-PLD and DAGL, respectively, in MIA-treated rats.
NAPE-PLD protein levels were significantly increased in the ipsilat-
eral spinal cord of MIA-treated rats compared with saline-treated rats.
There was significant protein expression of DAGL in the ipsilateral
spinal cord of MIA-treated rats, but the expression of DAGL protein
was at or below the limits of detection in saline-treated rats. n  6–8
rats per treatment group for gene expression data, and n  3 rats per
treatment group for protein data.   P  0.01 versus saline-treated
rats, by unpaired t-test.
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Based on the observation that endocannabinoid
levels are elevated but FAAH activity is similar in
MIA-treated rats versus saline-treated rats, the final
series of experiments investigated whether pharmaco-
logic blockade of the catabolism of anandamide by
FAAH, using URB597, had a differential effect in
MIA-treated rats compared with saline-treated rats.
Administration of URB597 (25–50 g/50 l) onto the
spinal cord significantly inhibited mechanically evoked
responses of WDR neurons in MIA-treated rats (Figure
5). The inhibitory effects of URB597 on 10 gm–evoked
responses were significantly (P  0.05) greater in MIA-
treated rats compared with saline-treated rats. URB597
had a comparable inhibitory effect on the noxious
(26 gm) mechanically evoked responses of WDR neu-
rons in MIA-treated rats and saline-treated rats.
DISCUSSION
This study is the first to assess the temporal
effects of MIA-induced knee joint pathology on pain
behavior and the responses of spinal dorsal horn neu-
rons. Although behavioral pain responses occurred from
day 7 onward, it was only between 28 days and 31 days
following MIA treatment that spinal neuronal responses
were facilitated, suggestive of spinal hyperexcitability.
The significant correlation between MIA-induced
changes in pain behavior (weight-bearing) and low
weight–evoked responses of neurons 28 days following
MIA injection provides evidence for an association
between pain behavior and neuronal responses at the
later time point. There was a significant correlation
between changes in subchondral bone histology and
Figure 5. Effects of spinal administration of the spinal cannabinoid 1 (CB1) receptor antagonist AM251 (0.1–10 g/50 l) (A–C), the
CB2 receptor antagonist SR144528 (0.001–0.1 g/50 l) (D–F), and the fatty acid amide hydrolase (FAAH) inhibitor URB597 (10–50
g/50 l) (G–I). Spinal administration of AM251 produced greater facilitation of 10 gm– and 15 gm–evoked responses of spinal
neurons in mono-iodoacetate (MIA)–treated rats (n 6 neurons in 6 rats) compared with saline-treated rats (n 6 neurons in 6 rats).
Spinal administration of SR144528 significantly facilitated mechanically (10–26 gm) evoked responses of wide dynamic range (WDR)
neurons in MIA-treated rats (n  6 neurons in 6 rats) but not saline-treated rats (n  6 neurons in 6 rats). Spinal administration of
URB597 significantly inhibited 10 gm– and 15 gm–evoked responses of WDR neurons in MIA-treated rats (n  7 neurons in 7 rats)
but not saline-treated rats (n  7 neurons in 7 rats), whereas 26 gm–evoked responses of WDR neurons were inhibited by URB597
in both MIA-treated and saline-treated rats. Data are expressed as mean and SEM maximal percent of the control response.   P 
0.05,   P  0.01 versus vehicle in MIA-treated rats;   P  0.05,   P  0.01 versus vehicle in saline-treated rats, by
Mann-Whitney test.
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mechanical allodynia on day 28, which supports the
proposal that bone pathology contributes to pain re-
sponses and central sensitization in OA (25). Collec-
tively, the decreased hind paw withdrawal thresholds
and increased responses of spinal neurons innervating
sites distal to the site of injury in MIA-treated rats are
consistent with the referred pain experienced by patients
with OA (26).
A novel finding of this study is that the levels of
anandamide, 2-AG, PEA, and OEA were elevated in the
spinal cords of MIA-treated rats. Neither mRNA/
protein levels nor the activities of FAAH and MAGL
(the major catabolic pathways for anandamide and
2-AG) were altered in the spinal cords of MIA-treated
rats compared with saline-treated control rats. Protein
levels of NAPE-PLD and DAGL, the major synthetic
enzymes for the N-acylethanolamines (anandamide,
PEA, and OEA) and 2-AG, respectively, were increased
in the spinal cords of MIA-treated rats compared with
saline-treated rats. Thus, the increased spinal cord levels
of anandamide, PEA, OEA, and 2-AG in MIA-treated
rats most likely arose as the result of increased synthesis
via NAPE-PLD and DAGL, respectively. The levels of
DAGL protein extracted from the spinal cords of
saline-treated rats were observed to be below the level of
detection by Western immunoblotting. DAGL has,
however, been shown to be present in postsynaptic
dorsal horn neurons of the spinal cord (27).
Increased mechanical responses of afferent fibers
(14,28,29) have been described in the MIA model. We
propose that this increased sensory input into the spinal
cord drives the observed facilitations in spinal cord
neuronal responses in MIA-treated rats, resulting in the
increased capacity of NAPE-PLD and DAGL to syn-
thesize anandamide and 2-AG, respectively. The bilat-
eral changes in the levels of N-acylethanolamines in
MIA-treated rats suggest that additional input into the
spinal cord may also contribute. Increased descending
facilitation from the rostral ventromedial medulla, which
has bilateral influence on spinal cord function in other
models of chronic pain (30) and is activated in patients
with OA (2), may also contribute.
Interestingly, mRNA levels of NAPE-PLD and
DAGL were not elevated alongside the protein levels.
There are limited data regarding the relationship be-
tween mRNA and protein expression for NAPE-PLD
and DAGL, although both enzymes can be regulated at
the transcription level (31,32). In the MIA model,
however, it appears that regulation occurs posttranscrip-
tionally, possibly at the level of translation or protein
degradation, and this possibility merits further investi-
gation.
Pharmacologic intervention with a CB1 receptor
antagonist provided evidence that the elevated spinal
cord levels of anandamide and 2-AG have a functional
role in this model of OA pain. Low weight (10 gm)–
evoked responses of spinal neurons in the MIA-treated
rats were facilitated by the CB1 receptor antagonist to a
greater extent than that seen in saline-treated rats.
These data are consistent with the established role of the
endocannabinoids in the tonic modulation of spinal
neuronal activity (33) and indicate that the elevated
spinal cord levels of endocannabinoids have a functional
role in limiting increases in the excitability of spinal
neurons, in particular those to low-weight mechanical
stimuli, which produce allodynia in this model. It is
noteworthy that CB1 receptor blockade did not modu-
late spinal cord responses to noxious knee compression
in a 14-day model of monarticular inflammation (34),
which may reflect differences in progression or the type
of model studied.
Remarkably, our functional data indicated that
along with CB1 receptors, spinal CB2 receptors are also
activated by elevated endocannabinoid levels in MIA-
treated rats but not in saline-treated rats. The ability of
a spinally administered CB2 receptor antagonist to facil-
itate evoked neuronal responses in MIA-treated rats
provides the first functional evidence for a spinal cord–
related role of CB2 receptors in this model of OA. CB2
receptor expression is increased and is associated with
activated microglia in the spinal cord in other models of
chronic pain (35,36); furthermore, spinally administered
CB2 receptor agonists are antinociceptive in models of
neuropathic pain (37; for review, see refs. 38 and 39).
Our data suggest that the potential role(s) of spinal cord
CB2 receptors in models of OA pain are worthy of
further investigation, and that this receptor may be a
novel target for the inhibition of OA-related pain.
Inhibitors of the enzymes responsible for catab-
olism of the endocannabinoids have therapeutic poten-
tial as novel analgesic treatments (16; for review, see ref.
40), the rationale being that chronic pain states are
associated with discrete increases in the levels of endo-
cannabinoids (for review, see ref. 10), and that prevent-
ing their catabolism could provide analgesic effects, with
limited CB1 receptor–mediated side effects. Spinal ad-
ministration of the FAAH inhibitor URB597 produced
dose-related inhibition of the evoked responses of spinal
neurons in MIA-treated rats. The inhibitory effects of
URB597 on low weight–evoked responses of spinal
neurons were greater in MIA-treated rats compared
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with saline-treated rats, which is consistent with the
increased spinal cord levels of anandamide in MIA-
treated rats and with CB1 and CB2 receptor antagonists
having greater effects on low weight–evoked responses
of spinal neurons in MIA-treated rats versus saline-
treated rats. These data suggest that the elevated spinal
cord levels of endocannabinoids play an important role
in the tonic modulation of low-weight (allodynic) input
in this model of OA pain, which can be potentiated by
reducing their catabolism by FAAH. Our group previ-
ously demonstrated, using identical experimental proto-
cols in neuropathic rats, that spinal administration of the
highest dose of URB597 used in this study elevated
levels of anandamide in the spinal cord, and that the
inhibitory effects of this dose of URB597 on neuronal
responses were blocked by a CB1 receptor antagonist
(16).
In conclusion, we have shown that the joint
pathology and pain behavior produced by intraarticular
injection of MIA is associated with increased excitability
of spinal neurons. This experimental model of OA pain
was associated with increased levels of endocannabi-
noids and NAPE-PLD and DAGL protein, both of
which contribute to the synthesis of these endocannabi-
noids. The elevated spinal cord levels of endocannabi-
noids appeared to have a greater functional inhibitory
role in the modulation of neuronal activity via CB1 and
CB2 receptors, in particular for low-weight mechanical
inputs, in the MIA model of OA. Consistent with these
data, spinal inhibition of FAAH had significantly greater
effects on low weight–evoked responses of spinal neu-
rons in MIA-treated rats. These mechanistic studies
have clinical implications, especially in the context of
mechanical allodynia, which is a major symptom of
chronic pain states and is poorly responsive to treatment
with conventional analgesics. Our study provides new
evidence for a crucial role of the endocannabinoids in
controlling neuronal excitability at the level of the spinal
cord in a clinically relevant model of OA pain.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Sagar had full access to all of the
data in the study and takes responsibility for the integrity of the data
and the accuracy of the data analysis.
Study conception and design. Sagar, Staniaszek, Okine, Norris, Pear-
son, Alexander, Bennett, Barrett, Kendall, Scammell, Chapman.
Acquisition of data. Sagar, Staniaszek, Okine, Woodhams, Norris,
Pearson, Garle, Alexander, Barrett, Scammell.
Analysis and interpretation of data. Sagar, Staniaszek, Okine, Norris,
Pearson, Garle, Alexander, Bennett, Barrett, Kendall, Scammell,
Chapman.
REFERENCES
1. Dieppe PA, Lohmander LS. Pathogenesis and management of
pain in osteoarthritis. Lancet 2005;365:965–73.
2. Gwilym SE, Keltner JR, Warnaby CE, Carr AJ, Chizh B, Chessell
I, et al. Psychophysical and functional imaging evidence supporting
the presence of central sensitization in a cohort of osteoarthritis
patients. Arthritis Rheum 2009;61:1226–34.
3. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K. Mono-
iodoacetate-induced histologic changes in subchondral bone and
articular cartilage of rat femorotibial joints: an animal model of
osteoarthritis. Toxicol Pathol 2003;31:619–24.
4. Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont
AJ, Hoyland JA, et al. Moderation of iodoacetate-induced exper-
imental osteoarthritis in rats by matrix metalloproteinase inhibi-
tors. Osteoarthritis Cartilage 2001;9:751–60.
5. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE,
Juneau PL, et al. Weight bearing as a measure of disease progres-
sion and efficacy of anti-inflammatory compounds in a model of
monosodium iodoacetate-induced osteoarthritis. Osteoarthritis
Cartilage 2003;11:821–30.
6. Combe R, Bramwell S, Field MJ. The monosodium iodoacetate
model of osteoarthritis: a model of chronic nociceptive pain in
rats? Neurosci Lett 2004;370:236–40.
7. Kobayashi K, Imaizumi R, Sumichika H, Tanaka H, Goda M,
Fukunari A, et al. Sodium iodoacetate-induced experimental
osteoarthritis and associated pain model in rats. J Vet Med Sci
2003;65:1195–9.
8. Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T,
et al. Pain related behaviour in two models of osteoarthritis in the
rat knee. Pain 2004;112:83–93.
9. Neugebauer V, Lucke T, Schaible HG. N-methyl-D-aspartate
(NMDA) and non-NMDA receptor antagonists block the hyper-
excitability of dorsal horn neurons during development of acute
arthritis in rat’s knee joint. J Neurophysiol 1993;70:1365–77.
10. Sagar DR, Gaw AG, Okine BN, Woodhams SG, Wong A, Kendall
DA, et al. Dynamic regulation of the endocannabinoid system:
implications for analgesia. Mol Pain 2009;5:59.
11. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T,
Iwase H, et al. Site-specific increases in peripheral cannabinoid
receptors and their endogenous ligands in a model of neuropathic
pain. Pain 2006;126:102–14.
12. Guasti L, Richardson D, Jhaveri M, Eldeeb K, Barrett D, Elphick
M, et al. Minocycline treatment inhibits microglial activation and
alters spinal levels of endocannabinoids in a rat model of neuro-
pathic pain. Molecular Pain 2009;5:35.
13. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione
S, et al. Changes in spinal and supraspinal endocannabinoid levels
in neuropathic rats. Neuropharmacology 2007;52:415–22.
14. Schuelert N, McDougall JJ. Cannabinoid-mediated antinocicep-
tion is enhanced in rat osteoarthritic knees. Arthritis Rheum
2008;58:145–53.
15. Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y,
et al. Inhibition of fatty acid amide hydrolase and cyclooxygen-
ase-2 increases levels of endocannabinoid related molecules and
produces analgesia via peroxisome proliferator-activated recep-
tor- in a model of inflammatory pain. Neuropharmacology
2008;55:85–93.
16. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman
V. Analgesic effects of fatty acid amide hydrolase inhibition in a
rat model of neuropathic pain. J Neurosci 2006;26:13318–27.
17. Chapman V, Suzuki R, Dickenson AH. Electrophysiological char-
acterization of spinal neuronal response properties in anaesthe-
tized rats after ligation of spinal nerves L5-L6. J Physiol 1998;507:
881–94.
18. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A,
ENDOCANNABINOID RECEPTOR SYSTEM IN A RAT MODEL OF OA PAIN 3675
et al. Modulation of anxiety through blockade of anandamide
hydrolysis. Nat Med 2003;9:76–81.
19. Richardson D, Ortori CA, Chapman V, Kendall DA, Barrett DA.
Quantitative profiling of endocannabinoids and related com-
pounds in rat brain using liquid chromatography-tandem electro-
spray ionization mass spectrometry. Anal Biochem 2007;360:
216–26.
20. Ghafouri N, Tiger G, Razdan RK, Mahadevan A, Pertwee RG,
Martin BR, et al. Inhibition of monoacylglycerol lipase and fatty
acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br J
Pharmacol 2004;143:774–84.
21. Erhuma A, Salter AM, Sculley DV, Langley-Evans SC, Bennett
AJ. Prenatal exposure to a low-protein diet programs disordered
regulation of lipid metabolism in the aging rat. Am J Physiol
Endocrinol Metab 2007;292:E1702–14.
22. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A,
et al. Antidepressant-like activity of the fatty acid amide hydrolase
inhibitor URB597 in a rat model of chronic mild stress. Biol
Psychiatry 2007;62:1103–10.
23. Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP,
Revell PA, et al. Osteoarthritis cartilage histopathology: grading
and staging. Osteoarthritis Cartilage 2006;14:13–29.
24. Mapp PI, Avery PS, McWilliams DF, Bowyer J, Day C, Moores S,
et al. Angiogenesis in two animal models of osteoarthritis. Osteo-
arthritis Cartilage 2008;16:61–9.
25. Ivanavicius SP, Ball AD, Heapy CG, Westwood FR, Murray F,
Read SJ. Structural pathology in a rodent model of osteoarthritis
is associated with neuropathic pain: increased expression of ATF-3
and pharmacological characterisation. Pain 2007;128:272–82.
26. Hendiani JA, Westlund KN, Lawand N, Goel N, Lisse J, McNear-
ney T. Mechanical sensation and pain thresholds in patients with
chronic arthropathies. J Pain 2003;4:203–11.
27. Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hoh-
mann AG, et al. Molecular architecture of endocannabinoid
signaling at nociceptive synapses mediating analgesia. Eur J Neu-
rosci 2009;29:1964–78.
28. Kelly S, Dunham JP, Murray F, Read S, Donaldson LF, Lawson
SN. Nociceptors in MIA osteoarthritic knee joints: spontaneous
firing in C-fibres and increased mechanosensitivity of A fibres.
In: International Association for the Study of Pain 12th World
Congress on Pain; 2008 Aug 17–22; Glasgow, Scotland, UK.
Seattle: IASP Press; 2008. p. PW145.
29. Schuelert N, McDougall JJ. Grading of monosodium iodoacetate-
induced osteoarthritis reveals a concentration-dependent sensiti-
zation of nociceptors in the knee joint of the rat. Neurosci Lett
2009;465:184–8.
30. Pertovaara A, Hamalainen MM, Kauppila T, Panula P. Carra-
geenan-induced changes in spinal nociception and its modulation
by the brain stem. Neuroreport 1998;9:351–5.
31. Nagy B, Fedonidis C, Photiou A, Wahba J, Paule CC, Ma D, et al.
Capsaicin-sensitive primary sensory neurons in the mouse express
N-Acyl phosphatidylethanolamine phospholipase D. Neuroscience
2009;161:572–7.
32. Walker DJ, Suetterlin P, Reisenberg M, Williams G, Doherty P.
Down-regulation of diacylglycerol lipase- during neural stem cell
differentiation: identification of elements that regulate transcrip-
tion. J Neurosci Res 2010;88:735–45.
33. Chapman V. The cannabinoid CB1 receptor antagonist,
SR141716A, selectively facilitates nociceptive responses of dorsal
horn neurones in the rat. Br J Pharmacol 1999;127:1765–7.
34. Telleria-Diaz A, Schmidt M, Kreusch S, Neubert AK, Schache F,
Vazquez E, et al. Spinal antinociceptive effects of cyclooxygenase
inhibition during inflammation: involvement of prostaglandins and
endocannabinoids. Pain 2010;148:26–35.
35. Racz I, Nadal X, Alferink J, Banos JE, Rehnelt J, Martin M, et al.
Crucial role of CB2 cannabinoid receptor in the regulation of
central immune responses during neuropathic pain. J Neurosci
2008;28:12125–35.
36. Romero-Sandoval A, Nutile-McMenemy N, DeLeo JA. Spinal
microglial and perivascular cell cannabinoid receptor type 2
activation reduces behavioral hypersensitivity without tolerance
after peripheral nerve injury. Anesthesiology 2008;108:722–34.
37. McGaraughty S, Chu KL, Dart MJ, Yao BB, Meyer MD. A CB2
receptor agonist, A-836339, modulates wide dynamic range neu-
ronal activity in neuropathic rats: contributions of spinal and
peripheral CB2 receptors. Neuroscience 2009;158:1652–61.
38. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a thera-
peutic target for the treatment of inflammatory and neuropathic
pain. Br J Pharmacol 2008;153:319–34.
39. Sagar DR, Kelly S, Millns PJ, O’Shaughnessey CT, Kendall DA,
Chapman V. Inhibitory effects of CB1 and CB2 receptor agonists
on responses of DRG neurons and dorsal horn neurons in
neuropathic rats. Eur J Neurosci 2005;22:371–9.
40. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that
regulate endocannabinoid signaling in the nervous system. Chem
Rev 2008;108:1687–707.
3676 SAGAR ET AL
